TY  - JOUR
AU  - Alegre, Adrián
AU  - de la Rubia, Javier
AU  - Sureda Balari, Anna
AU  - Encinas Rodríguez, Cristina
AU  - Suárez, Alexia
AU  - Blanchard, María Jesús
AU  - Bargay Lleonart, Joan
AU  - Rodríguez-Otero, Paula
AU  - Insunza, Andrés
AU  - Palomera, Luis
AU  - Peñarrubia, María Jesús
AU  - Ríos-Tamayo, Rafael
AU  - Casado Montero, Luis Felipe
AU  - González, Marta Sonia
AU  - Potamianou, Anna
AU  - Couturier, Catherine
AU  - Pei, Huiling
AU  - Hevia, Henar
AU  - Milionis, Iordanis
AU  - Gaudig, Maren
AU  - Mateos, María-Victoria
PY  - 2020
DO  - 10.1097/HS9.0000000000000380
UR  - https://hdl.handle.net/10668/27125
T2  - HemaSphere
AB  - Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access...
LA  - en
TI  - Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.
TY  - research article
VL  - 4
ER  -